对于阿尔茨海默病的γ-分泌酶的新兴结构和动态机制
Yinglong Miao1, Michael S Wolfe2
1Computational Medicine Program and Department of Pharmacology, University of North Carolina - Chapel Hill, Chapel Hill, NC, USA.
Neural regeneration research
|May 20, 2024
概括
本综述探讨了玛分泌酶 (γ-分泌酶) 在粉样蛋白前体蛋白等基质分裂中的动态机制. 了解这些过程,包括家族性阿尔茨海默病突变,是开发新疗法的关键.
科学领域:
- 分子生物学和生物化学 分子生物学和生物化学
- 神经科学是一个神经科学.
- 结构生物学 结构生物学
背景情况:
- 密酶 (γ-secretase) 是一种关键的嵌入膜的蛋白酶复合体,参与了超过150个基质的分裂.
- γ-分泌酶和粉样蛋白前体蛋白的功能障碍与早期家族性阿尔茨海默病 (AD) 有关,使得 γ-分泌酶成为重要的药物标.
- 在了解γ-分泌酶的基质加工机制,AD突变的影响和全调制方面存在差距.
研究的目的:
- 审查最近关于γ-分泌酶的结构和动态机制的研究.
- 阐明基质蛋白解的机制,特别是对于粉样蛋白前体蛋白和诺奇受体.
- 讨论家族性阿尔茨海默病突变对γ-分泌酶功能和基质相互作用的影响.
主要方法:
- 对粉样蛋白前体蛋白质提出的"适应-保持-修剪"",滑动-解"和"倾斜-解"蛋白质解机制的分析.
- 使用全原子分子动力学模拟来研究基质裂解机制.
- 重建和模拟Notch1-bound γ-secretase模型以分析基质注册和激活.
主要成果:
- 分子动力学模拟提供了关于由γ-分泌酶对粉样蛋白前体蛋白分裂的拟议机制的见解.
- 模拟成功捕获了γ-分泌酶激活,用于适当地切割野生型和突变的诺奇,解决了与冷-EM结构的差异.
- 这项研究讨论了关于家族性阿尔茨海默病突变是否稳定或不稳定γ-分泌酶-基质复合物的持续争议.
结论:
- 了解γ-分泌酶的动态机制对于破译基质加工和AD突变的影响至关重要.
- 分子动力学模拟提供了一种强大的方法来研究γ-分泌酶功能,可以应用于各种基质.
- 对基质结合,产品释放和调节效应的进一步研究将有助于合理设计有效的阿尔茨海默病治疗方法.
相关概念视频
Alzheimer's Disease: Overview
465
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
465
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Alzheimer's Disease: Treatment
180
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
180


